A team of subject matter experts from across the National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA) has drafted Target Product Profiles (TPPs) for potential direct-acting antiviral therapeutics candidates targeting several key viruses of pandemic potential. These TPPs should be considered ‘living documents’ that are never final but may be useful starting points for consideration by therapeutics developers who are drafting TPPs for their specific candidates. Also, the example TPPs are not intended to provide details about product requirements for funding or other support from USG or other funders. Instead, these sample TPPs are being provided as tools for scientists working toward therapeutics product development of direct-acting antivirals for use in early treatment of infections during future outbreaks or pandemics.
Target Product Profiles
- Arenaviruses
- Bunyaviruses – Hantavirus
- Bunyaviruses – Rift Valley Fever Virus (RVFV), Crimean-Congo Hemorrhagic Fever Virus (CCHFV), and Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)
- Coronaviruses – SARS-CoV-1 and MERS-CoV
- Coronaviruses – SARS-CoV-2
- Filoviruses – Ebola Virus Disease (EVD), Marburg Virus Disease (MVD)
- Flaviviruses – Dengue Virus (DENV)
- Flaviviruses – Neuroinvasive disease caused by West Nile Virus (WNV) and Japanese Encephalitis Virus (JEV)
- Flaviviruses – Yellow Fever Virus (YFV)
- Flaviviruses – Zika Virus (ZIKV)
- Paramyxoviruses – Nipah Virus
- Picornaviruses – Neurological disease caused by Enterovirus (EV) infection (meningitis, encephalitis, acute flaccid myelitis (AFM), acute flaccid paralysis (AFP))
- Togaviruses – Arthropathic disease caused by Chikungunya Virus (CHIKV)
- Togaviruses – Encephalitic disease caused by Venezuelan Equine Encephalitis Virus (VEEV), Western Equine Encephalitis Virus (WEEV), and Eastern Equine Encephalitis Virus (EEEV)